Spago Nanomedical AB

Spago Nanomedical AB (publ) is a Swedish nanomedicine company in clinical development phase, developing products for diagnostics and treatment of life-threatening diseases. The company's operations are based on a patented material for the design of functional nanoparticles that accumulate physilogically in tumors, thus enabling higher precision and improved cancer patient care. The current pipeline projects have the potential to facilitate diagnostics and improve the treatment of cancer indications with urgent medical needs.

Spago Nanomedicals proprietary nanomaterial is designed to selectively accumulate in tumor tissue based on a well described principle called the Enhanced Permeability and Retention (EPR) effect. Spago’s nanomedical platform is made up by an organophosphosilane core with excellent chelating properties. By chelating a therapeutic radioisotope (177Lu; Tumorad) or the paramagnetic ion manganese (Mn; SpagoPix), Spago Nanomedical addresses significant clinical needs for treatment of aggressive tumor-resistant and metastatic cancer, and high-precision and high-resolution imaging of solid tumors and metastases.

The nanoparticle core is protected by a proprietary PEG-based coating which reduces protein binding and renders the particles long circulation half-lives. The size of the particles will dictate biodistribution and can be fine-tuned and optimized based on the sough after properties for the target indications.